Cosmo Pharmaceuticals N.V.
CMOPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $869,559 | $1,057,340 | $1,207,731 | $765,181 |
| - Cash | $50,749 | $44,296 | $54,556 | $50,275 |
| + Debt | $2,699 | $2,201 | $1,455 | $1,839 |
| Enterprise Value | $821,509 | $1,015,245 | $1,154,630 | $716,745 |
| Revenue | $51,720 | $130,551 | $136,237 | $49,119 |
| % Growth | -60.4% | -4.2% | 177.4% | – |
| Gross Profit | $26,149 | $133,836 | $113,087 | $28,650 |
| % Margin | 50.6% | 102.5% | 83% | 58.3% |
| EBITDA | $4,852 | $71,459 | $94,246 | $5,665 |
| % Margin | 9.4% | 54.7% | 69.2% | 11.5% |
| Net Income | -$2,006 | $57,245 | $75,991 | -$6,418 |
| % Margin | -3.9% | 43.8% | 55.8% | -13.1% |
| EPS Diluted | -0.13 | 3.43 | 4.71 | -0.4 |
| % Growth | -103.8% | -27.2% | 1,277.5% | – |
| Operating Cash Flow | $900 | $63,225 | $99,186 | $18,140 |
| Capital Expenditures | -$2,624 | -$4,225 | -$1,428 | -$1,907 |
| Free Cash Flow | -$1,724 | $59,000 | $97,758 | $16,233 |